Novavax, Inc. (NVAX) is a Gaithersburg, Maryland-based biotechnology company that develops and commercializes vaccines, including its Nuvaxovid COVID-19 vaccine and its Matrix-M adjuvant. Nine credible, current analyst price targets were reviewed to establish the central target. They span a very wide range of $6 to $25, and their arithmetic mean of about $13.78 rounds to a central target of $14.
The dispersion is the story. On the bullish side, Jefferies holds a $25 target (maintained in March 2026) and views Novavax as a capital-light adjuvant platform rather than merely a COVID-royalty story. Cantor Fitzgerald ($18), BTIG ($19), H.C. Wainwright ($16), and B. Riley Securities ($16, trimmed from $18 in November 2026) carry Buy ratings. On the cautious side, TD Cowen ($9, Hold), Bank of America ($8, Sell), Citigroup ($8, Sell), and J.P. Morgan ($6, Sell) emphasize shrinking revenue, cash burn, and execution risk. The mean should be read as a midpoint across genuinely divergent views, not as a guarantee.
Novavax shares closed near $10.20 on November 10, 2026, giving the company a market capitalization of roughly $1.7 billion. Reaching $14 would require an advance of about 37%, which qualifies as a substantial move. The stock's 52-week range is approximately $6.20 to $13.39.
The path would likely depend on continued execution of a licensing and royalty model built around Sanofi, which triggered a $125 million milestone payment in late 2026 when it launched a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. Novavax reported third-quarter 2026 revenue of $68.3 million and a sharply narrowed net loss of $31.4 million, and management has pointed to a cash runway into 2029. Still, revenue is contracting from a 2025 peak of about $1.12 billion, and the company is not yet consistently profitable on a GAAP (generally accepted accounting principles) basis.
The stock trades below its 50-day moving average near $10.61 but above its 200-day moving average near $9.34. The 52-week high near $13.39, set in early October 2026, stands as the nearest major resistance before the $14 target. Support sits around the $10 psychological level and the 200-day average near $9.34, with the 52-week low near $6.20 farther below.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. Investors should watch quarterly earnings and guidance, Sanofi's combination-vaccine clinical and commercial progress, milestone and royalty recognition, analyst target revisions, and any changes in partnership terms or the broader biotechnology funding environment.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For those following names like Novavax alongside the broader market, the signals offer a way to stay current on daily developments without constant chart watching.
The $14 central target is the average of nine verified analyst price targets spanning $6 to $25, and it implies a substantial gain of roughly 37% from a price near $10.20. The bull case rests on Sanofi milestones, royalties, and a capital-light licensing model, while the bear case centers on contracting revenue, cash burn, and dependence on partner execution. With such a wide analyst range, the target is best understood as a midpoint across competing narratives rather than a forecast. Investors should monitor partnership milestones, quarterly results, and analyst revisions as the key inputs to whether the shares can close the gap toward $14.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To NVAX | 1D Price Change % | ||
|---|---|---|---|---|
| NVAX | 100% | -2.68% | ||
| CRSP - NVAX | 54% Loosely correlated | -0.89% | ||
| ARCT - NVAX | 51% Loosely correlated | -0.95% | ||
| RXRX - NVAX | 49% Loosely correlated | -4.35% | ||
| MRNA - NVAX | 48% Loosely correlated | -3.45% | ||
| PCVX - NVAX | 48% Loosely correlated | -2.04% | ||
More | ||||